DURECT is leveraging its epigenetic regulator program and proprietary drug delivery technologies to develop novel and lifesaving therapies for a wide range of diseases with few current treatment options.
DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.
DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.
January 5, 2021
January 4, 2021
December 21, 2020
An investigational non-opioid, locally-acting analgesic being evaluated for its ability to provide 3 days of continuous pain relief after surgery.
LEARN MORE >